| Literature DB >> 22629447 |
Adam J Ritchie1, Kristin Kuldanek, Zoe Moodie, Z Maggie Wang, Julie Fox, Rebecca N Nsubuga, Kenneth Legg, Esther F Birabwa, Pontiano Kaleebu, Andrew J McMichael, Christine Watera, Nilu Goonetilleke, Sarah Fidler.
Abstract
BACKGROUND: The CHAVI002 study was designed to characterize immune responses, particularly HIV-specific T-cell responses, amongst 2 cohorts of HIV-exposed seronegative (HESN) individuals. The absence of a clear definition of HESNs has impaired comparison of research within and between such cohorts. This report describes two distinct HESN cohorts and attempts to quantify HIV exposure using a 'HIV risk index' (RI) model.Entities:
Mesh:
Year: 2012 PMID: 22629447 PMCID: PMC3358272 DOI: 10.1371/journal.pone.0037727
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
The risk factors and odds ratios used to generate the risk index (RI) in the current study.
| Factor | HESN susceptibility | HIV+ infectiousness |
| Viral load (Log10) | ||
| 0–3.49 | 1 | |
| 3.50–4.16 | 5.8 | |
| 4.17–4.88 | 6.91 | |
| >4.88 | 11.87 | |
| Male circumcised | 0.47 | 1 |
| GUD | 2.58 | 2.04 |
| Pregnancy | 2.16 | 1 |
Summary of Study Group Characteristics for UK and Uganda.
| UK | Uganda | ||||||
| HESN (n = 24) | HIV+ (n = 24) | HUSN (n = 28) | HESN (n = 72) | HIV+ (n = 72) | HUSN (n = 55) | ||
|
| 35 (30.5–47) | 37 (29–43) | 29.5 (27–33.5) | 30 (26.5–40.5) | 34.5 (28–40.5) | 32 (26–37) | |
|
| 24 (100%) | 23 (96%) | 19 (68%) | 34 (47%) | 38 (53%) | 29 (53%) | |
|
| 2/24 (8%) | 2/23 (9%) | 3/19 (16%) | 16/34 (47%) | 10/38 (26%) | 11/29 (38%) | |
|
| 23 (96%) | 23 (96%) | 10 (36%) | 0 (0%) | 0 (0%) | 0 (0%) | |
|
| 24 (100%) | 22 (92%) | 24(86%) | 0 (0%) | 0 (0%) | 0 (0%) | |
|
| 0 (0%) | 0 (0%) | 2 (7%) | 72 (100%) | 72 (100%) | 55 (100%) | |
|
| 23 (15–54) | 20 (15–41) | 39 (33–55) | 64 (37–149) | 66 (36–151) | 74 (38–112) | |
|
| 2/24 (8%) | 4/24 (17%) | 1/24 (4%) | 14/72 (19%) | 11/72 (15%) | 23/55 (42%) | |
|
| N/A | 17 (70.8%) | N/A | N/A | 25 (34.7%) | N/A | |
|
| N/A | n = 23 | N/A | N/A | n = 71 | N/A | |
|
| N/A | n = 16<50 (<50–170) | N/A | N/A | n = 24<400 (<400–51 400) | N/A | |
|
| N/A | n = 7 14 054 (<50–340 581) | N/A | N/A | n = 47 21 900 (<400-2 830 000) | N/A | |
|
| N/A | n = 23 | N/A | N/A | n = 72 233.5 (49–735) | N/A | |
|
| N/A | n = 16 540 (230–1080) | N/A | N/A | n = 25 265 (77–641) | N/A | |
|
| N/A | n = 7 690 (10–789) | N/A | N/A | n = 47 229 (49–735) | N/A | |
IQR; Interquartile range.
No participants self-identified as bisexual, therefore those not identified as MSM are heterosexual.
Participants positive for Chlamydia, Gonorrhoea, GUD, Bacterial Vaginosis, Candidiasis, and/or Syphilis at any study visit, and/or reporting incidences of genital lesions/discharge/rash/itching in the 3 months preceding any study visit.
No pVL data available for one UK and one Ugandan HIV+ participant at visit 1.
Limit of detection 50 copies/ml in UK and 400 copies/ml in Uganda samples.
No CD4+ count data for one UK HIV+ participant at visit 1.
Data from visit 1 summarising key sexual behavior acts (with ejaculation and no condom use) reported within the past 3 months and the proportion of couples who were concordant in their responses across all sex acts.
| UK | Uganda | ||||||
| HESN n = 24 | HIV+ n = 24 | HUSN n = 28 | HESN n = 72 | HIV+ n = 72 | HUSN n = 55 | ||
| Insertive anal intercourse median (range) | 6 (0–40) | 0 (0–3) | 3 (0–12) | NR | NR | NR | |
| Receptive anal intercourse median (range) | 0 (0–2) | 4 (0–50) | 3.5 (0–38) | NR | NR | NR | |
| Vaginal intercourse median (range) | 3 | 12 | 19 (0–36) | 12 (0–150) | 12 (0–524) | 30 (0–48) | |
| Received oral sex median (range) | 2 (0–24) | 0 (0–50) | 3.5 (0–30) | 1 (0–14) | 9 (0–24) | 4 (0–42) | |
| Gave oral sex median (range) | 0 (0–36) | 1 (0–50) | 4 (0–30) | 2 (0–18) | 1 (0–3) | 2 (0–42) | |
| Concordance of responses | HESN/HIV+24 couples | HUSN 14 couples | HESN/HIV+72 couples | HUSN 25 couples | |||
| Past 7 days | |||||||
| With oral | 20/20 (100%) | 13/13 (100%) | 28/32 (88%) | 22/22 (100%) | |||
| Without oral | 20/20 (100%) | 13/13 (100%) | 29/30 (97%) | 22/22 (100%) | |||
| Past 3 months | |||||||
| With oral | 12/24 (50%) | 8/14 (57%) | 55/69 (80%) | 19/25 (76%) | |||
| Without oral | 19/24 (79%) | 11/14 (79%) | 58/69 (84%) | 20/25 (80%) | |||
| Most active week | |||||||
| With oral | 20/24 (83%) | 13/13 (100%) | 64/70 (91%) | 25/25 (100%) | |||
| Without oral | 20/24 (83%) | 13/13 (100%) | 64/70 (91%) | 25/25 (100%) | |||
NR; none reported.
Single data point only.
Figure 1Sexual behavior scores (SBSs) across visits for study groups in the UK1 (top row) and Uganda (bottom row) cohorts.
Boxplots of SBSs of concordant individuals are shown, where the midline and box represent the median ± the 25th and 75th percentiles; whiskers extend to the extreme data points that are ≤1.5 times the interquartile range. Extreme outliers are indicated by circles. 1Note that the scales of the y-axis for UK HIV+ and HUSN are much larger than those of the other groups. *One UK HESN with a very large SBS at Visit 3 (0.126) is not shown in order to maintain a comparable scale over plots where possible.
Figure 2Risk indexes (RIs) for HESN participants in the UK and Ugandan cohorts over 4 visits.
RIs were generated based on reported sexual behaviors for the last 3 months (if concordant with answers from the HIV+ study partner), partner HIV-1 pVL, concurrent STIs, male circumcision status, and pregnancy. Boxplots of RI are shown, where the midline and box represent the median ± the 25th and 75th percentiles; whiskers extend to the extreme data points that are ≤1.5 times the interquartile range. Extreme outliers are indicated by circles.